{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":47,"n_cols":5,"rows_kept":47,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[7,2,7,3],[8,2,8,3],[10,2,10,3],[13,2,13,3],[14,2,14,3],[18,2,18,3],[26,2,26,3],[26,4,26,5],[27,2,27,3],[27,4,27,5],[28,2,28,3],[28,4,28,5],[29,2,29,3],[31,2,31,3],[35,2,35,3],[36,2,36,3],[37,2,37,3],[40,2,40,3],[41,2,41,3],[45,2,45,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910829843803321"]
[null,null,"Titolo",null,"DNA pharmaceuticals [[electronic resource] ] : formulation and delivery in gene therapy, DNA vaccination and immunotherapy / / edited by Martin Schleef"]
[null,null,"Pubbl/distr/stampa",null,"Weinheim, : Wiley-VCH, c2005"]
[null,null,"ISBN",null,"1-280-85409-X"]
[{"$nulls":4},"9786610854097"]
[{"$nulls":4},"3-527-60753-6"]
[{"$nulls":4},"3-527-60700-5"]
[null,null,"Descrizione fisica",null,"1 online resource (277 p.)"]
[null,null,"Disciplina",null,"615.372"]
[{"$nulls":4},"616.0796"]
[null,null,"Soggetti",null,"DNA vaccines"]
[{"$nulls":4},"Gene therapy"]
[{"$nulls":4},"Immunotherapy"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"DNA Pharmaceuticals; Preface; Contents; List of Contributors; Abbreviations; 1 DNA Vaccines - An Overview; 1.1 Rationale for DNA Vaccines; 1.2 Preclinical Proof of Concept; 1.3 Clinical Trials; 1.4 Second-Generation Vaccines; 1.5 Conclusions; References; 2 DNA as a Pharmaceutical - Regulatory Aspects; 2.1 Introduction; 2.2 Quality Requirements for DNA used as a Gene Therapy Product; 2.2.1 Introduction; 2.2.2 Production and Purification; 2.2.2.1 Raw Materials; 2.2.2.2 Antibiotics; 2.2.2.3 Solvents; 2.2.2.4 Fermentation; 2.2.2.5 Purification; 2.2.3 Cell Banking System Procedures"]
[{"$nulls":4},"2.2.3.1 Generation and Characterization of Master and Working Cell Banks2.2.4 Product Characterization and Quality Criteria; 2.2.4.1 Identity; 2.2.4.2 Purity; 2.2.4.3 Adventitious Agents; 2.2.4.4 Potency; 2.3 Safety Studies for Clinical Trials; 2.3.1 General Considerations; 2.3.2 Conduct of Preclinical Safety Studies; 2.3.2.1 Regulations; 2.3.2.2 Design of an Appropriate Toxicology Program; 2.3.2.3 Single- and Repeat-Dose Toxicity Studies; 2.3.2.4 Safety of the Formulated Plasmid DNA; 2.3.2.5 Specific Safety Considerations; 2.3.2.6 Choice of Animal Model; 2.4 Special Issues"]
[{"$nulls":4},"2.4.1 Comparability of Plasmid Gene Therapy Products2.4.2 Mixed "]
[{"$nulls":4},"Plasmid Preparations; 2.4.3 Plasmid Molecular Structure; 2.5 Biosafety Issues and Environmental Risk Assessment; References; 3 From Bulk to Delivery: Plasmid Manufacturing and Storage; 3.1 Introduction; 3.1.1 Gene Therapy; 3.1.2 DNA Vaccination; 3.2 Manufacturing of Plasmid DNA; 3.2.1 Bacterial Cultivation; 3.2.2 Plasmid DNA Purification; 3.2.3 Innovative Aspects in Plasmid Manufacturing; 3.3 Quality Control of Plasmid DNA Vectors; 3.3.1 Proteins, Ribonucleic Acid, and Lipopolysaccharides; 3.3.2 Chromosomal DNA"]
[{"$nulls":4},"3.3.3 Plasmid Identity3.3.4 Plasmid Topology (Structural Homogeneity); 3.4 Plasmid Stability during Storage and Application; 3.4.1 Long-Term Stability of Plasmid DNA; 3.4.2 Lyophilization for Long-Term Storage; 3.4.3 Stability during Application; 3.5 Future Developments; References; 4 Minimized, CpG-Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy; 4.1 Introduction; 4.2 The Mammalian Immune System as a Barrier to Nonviral Gene Delivery; 4.3 Strategies to Minimize DNA Vectors"]
[{"$nulls":4},"4.3.1 Excision of a DNA Fragment Containing a Transgene Expression Cassette from Plasmid DNA4.3.2 Intramolecular Site-Specific Recombination Within a Bacterial Plasmid; 4.3.3 Synthesis of Minimized DNA Vectors by PCR; 4.3.4 Improvement of Minimized DNA Vector Yield and Purity; 4.4 Depletion of CpG Dinucleotides in the Bacterial Vector Backbone; 4.5 Methylation of CpG Dinucleotides in Plasmid DNA; 4.6 Towards an Ideal Nonviral Vector; 4.7 Conclusion; References; 5 Localized Nucleic Acid Delivery: A Discussion of Selected Methods; 5.1 Foreword; 5.2 Nucleic Acid Delivery - What For?"]
[{"$nulls":4},"5.3 Nucleic Acid Delivery - How?"]
[null,null,null,"Sommario/riassunto","With its focus on a completely novel class of pharmaceuticals, this book collates the hitherto scarce literature about DNA drug formulation keenly desired by biotechnologists, molecular biologists and pharmacists, as well as those working in the biotechnological and pharmaceutical industries.As such, this volume presents a wide range of gene delivery systems needed for different therapeutic applications. It fills the gap between research and clinical trials and describes pharmaceutical fundamentals for the development of efficient DNA pharmaceuticals."]
[null,"2.","Record Nr.",null,"UNINA9910807370303321"]
[null,null,"Autore",null,"Morisy Ann"]
[null,null,"Titolo",null,"Borrowing from the future : a faith-based approach to intergenerational equity / / Ann Morisy"]
[null,null,"Pubbl/distr/stampa",null,"London, [England] ; ; New York, New York : , : Continuum, , 2011"]
[{"$nulls":4},"©2011"]
[null,null,"ISBN",null,"1-4411-1048-8"]
[{"$nulls":4},"1-283-12236-7"]
[{"$nulls":4},"9786613122360"]
[{"$nulls":4},"1-4411-1009-7"]
[null,null,"Descrizione fisica",null,"1 online resource (238 p.)"]
[null,null,"Disciplina",null,"248.483"]
[null,null,"Soggetti",null,"Social policy"]
[{"$nulls":4},"Baby boom generation"]
[{"$nulls":4},"Intergenerational relations"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Includes index."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Cover; Contents; Acknowledgements; Introduction; 1 Uniquely favoured? Uniquely selfish? Uniquely fearful?; 2 What's the score?; 3 Borrowing from the future; 4 Second chance theology; 5 Age has its purpose?; 6 Retirement matters; 7 Inheritance matters; 8 An epidemic of narcissism?; 9 Pivot: Paying our proper dues; 10 Old people . . . don't make me laugh; 11 Resentment: The dastardly bushfire; Questions for Discussion; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; Q; R; S; T; U; V; W; Z"]
[null,null,null,"Sommario/riassunto","This is a new but pressing issue.   The pukka term is 'intergenerational equity' and gerontologists and policy makers have seen it coming for some time.   The recession has added to the intensity of the issue, as those in the later stage of life are less likely to be hard hit by changes in relation to pension provision, unemployment and the steep challenge of getting a foot on the property ladder.   Societies throughout history have been used to investing in their children, today the worry is the ever rising cost of eldercare.   There are profound, but unacknowledged repercussions of the age p"]